ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. LoRusso on Personalized Medicine for Melanoma

Patricia M. LoRusso, DO
Published: Wednesday, Apr 15, 2015



Patricia M. LoRusso, DO, Associate Director of Innovative Medicine, Yale Cancer Center, discusses the Dream Team Melanoma trial, which is investigating using personalized medicine to treat non-V600E melanoma subtypes.

All the patients on the trial have progressed on immunotherapy and are now in need of additional treatment. Currently, there are no targeted therapies approved by the FDA for this subset of patients.

By using genotyping, individualized treatments are selected for each of theses patient based on their tumor, explains LoRusso. This approach is predicted to be more effective than the standard of care.


Patricia M. LoRusso, DO, Associate Director of Innovative Medicine, Yale Cancer Center, discusses the Dream Team Melanoma trial, which is investigating using personalized medicine to treat non-V600E melanoma subtypes.

All the patients on the trial have progressed on immunotherapy and are now in need of additional treatment. Currently, there are no targeted therapies approved by the FDA for this subset of patients.

By using genotyping, individualized treatments are selected for each of theses patient based on their tumor, explains LoRusso. This approach is predicted to be more effective than the standard of care.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Publication Bottom Border
Border Publication
x